113 related articles for article (PubMed ID: 22166275)
41. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors.
Ashoor G; Poon L; Syngelaki A; Mosimann B; Nicolaides KH
Fetal Diagn Ther; 2012; 31(4):237-43. PubMed ID: 22572044
[TBL] [Abstract][Full Text] [Related]
42. Renal hemodialysis and maternal serum triple analyte screening.
Shulman LP; Briggs R; Phillips OP; Friedman SA; Sibai B
Fetal Diagn Ther; 1998; 13(1):26-8. PubMed ID: 9605612
[TBL] [Abstract][Full Text] [Related]
43. Maternal serum screening for fetal genetic disorders.
Ross HL; Elias S
Obstet Gynecol Clin North Am; 1997 Mar; 24(1):33-47. PubMed ID: 9086517
[TBL] [Abstract][Full Text] [Related]
44. Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction.
Groutz A; Amit A; Yaron Y; Yovel I; Wolman I; Legum C; Lessing JB
Prenat Diagn; 1996 Aug; 16(8):723-7. PubMed ID: 8878282
[TBL] [Abstract][Full Text] [Related]
45. Autism Spectrum Disorder Risk in Relation to Maternal Mid-Pregnancy Serum Hormone and Protein Markers from Prenatal Screening in California.
Windham GC; Lyall K; Anderson M; Kharrazi M
J Autism Dev Disord; 2016 Feb; 46(2):478-88. PubMed ID: 26370672
[TBL] [Abstract][Full Text] [Related]
46. Utility of the triple test in the detection of abnormalities of the feto-placental unit.
Perenc M; Dudarewicz L; Kałuzewski B
Med Sci Monit; 2000; 6(5):994-9. PubMed ID: 11208444
[TBL] [Abstract][Full Text] [Related]
47. Serum markers for Down's syndrome in relation to number of previous births and maternal age.
Wald NJ; Watt HC
Prenat Diagn; 1996 Aug; 16(8):699-703. PubMed ID: 8878278
[TBL] [Abstract][Full Text] [Related]
48. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
[TBL] [Abstract][Full Text] [Related]
49. Practical strategies in contingent sequential screening for Down syndrome.
Benn P; Wright D; Cuckle H
Prenat Diagn; 2005 Aug; 25(8):645-52. PubMed ID: 16049988
[TBL] [Abstract][Full Text] [Related]
50. Maternal serum screening for birth defects: results of a Connecticut regional program.
Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
[TBL] [Abstract][Full Text] [Related]
51. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
[TBL] [Abstract][Full Text] [Related]
52. Revised distribution parameters for serum markers for trisomy 18.
Hackshaw AK; Wald NJ
J Med Screen; 2000; 7(4):215. PubMed ID: 11202590
[No Abstract] [Full Text] [Related]
53. Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S; Bindra R; Rembouskos G; Spencer K; Nicolaides KH
Prenat Diagn; 2003 Apr; 23(4):306-10. PubMed ID: 12673635
[TBL] [Abstract][Full Text] [Related]
54. Medians and correction factors for biochemical and ultrasound markers in Chinese women undergoing first-trimester screening for trisomy 21.
Sahota DS; Leung TY; Fung TY; Chan LW; Law LW; Lau TK
Ultrasound Obstet Gynecol; 2009 Apr; 33(4):387-93. PubMed ID: 19306471
[TBL] [Abstract][Full Text] [Related]
55. Maternal serum pregnancy-associated plasma protein A (PAPP-A) but not pregnancy-specific beta1-glycoprotein (SP1) is a useful second-trimester marker for fetal trisomy 18.
Bersinger NA; Leporrier N; Herrou M; Leymarie P
Prenat Diagn; 1999 Jun; 19(6):537-41. PubMed ID: 10416969
[TBL] [Abstract][Full Text] [Related]
56. Co-variables in first trimester maternal serum screening.
de Graaf IM; Cuckle HS; Pajkrt E; Leschot NJ; Bleker OP; van Lith JM
Prenat Diagn; 2000 Mar; 20(3):186-9. PubMed ID: 10719318
[TBL] [Abstract][Full Text] [Related]
57. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
58. [Evaluation of pregnancy-associated plasma protein A (PAPP-A) and free beta subunit of human chorionic gonadotropin (beta hCG) levels and sonographic assesement of fetal nuchal translucency (NT) in singleton pregnancies between 11 and 14 weeks of gestation--Polish multi-centre research].
Borowski D; Czuba B; Cnota W; Hincz P; Czekierdowski A; Gajewska J; Jaczyńska R; Ceran A; Włoch A; Wyrwas D; Wiełgoś M; Szymusik I; Szaflik K; Sodowski K
Ginekol Pol; 2007 May; 78(5):384-7. PubMed ID: 17867331
[TBL] [Abstract][Full Text] [Related]
59. Participation in maternal serum screening following screen positive results in a previous pregnancy.
Rausch DN; Lambert-Messerlian GM; Canick JA
J Med Screen; 2000; 7(1):4-6. PubMed ID: 10807139
[TBL] [Abstract][Full Text] [Related]
60. The best marker combination using the integrated screening test approach for detecting various chromosomal aneuploidies.
Maymon R; Sharony R; Grinshpun-Cohen J; Itzhaky D; Herman A; Reish O
J Perinat Med; 2005; 33(5):392-8. PubMed ID: 16238533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
